Allergies, Author Interviews, Dermatology / 06.12.2025

[caption id="attachment_71677" align="alignleft" width="200"]Dr. Shaila Gogate, MDColorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator  Dr. Gogate[/caption] MedicalResearch.com Interview with: Dr. Shaila Gogate, MD Colorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? A: The Phase III REMIX-1/-2 studies were randomized, double-blind, placebo-controlled studies assessing the efficacy and safety of oral  remibrutinib 25 mg twice daily or placebo over a 24-week double-blind period, followed by a 28-week open-label remibrutinib treatment period. The purpose of this pooled analysis was to examine the early and long-term efficacy data of remibrutinib vs. placebo over time, looking at the mean percentage change from baseline (CFB) in weekly scores of disease activity (UAS7), itch severity (ISS7) and hives severity (HSS7) over 52 weeks. This analysis demonstrated that remibrutinib showed reductions in urticaria symptoms vs. placebo as early as week 1:
    • 38.4% vs. 10.3% in UAS7
    • 37.0% vs. 9.8% in ISS7
    • 39.8% vs. 10.1% HSS7 Greater reductions vs. placebo were seen over 24 weeks and results were observed in the open-label period through week 52 in all remibrutinib-treated patients (including those transitioned from placebo).
Allergies, Author Interviews, Dermatology / 05.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71671" align="alignleft" width="133"]Dr. Giselle Mosnaim MD MSAllergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator Dr. Mosnaim[/caption] Dr. Giselle Mosnaim MD MS FACAAI Allergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment. The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Allergies, Author Interviews, Pets / 16.10.2025

[caption id="attachment_71022" align="aligncenter" width="500"]freepx-cockroach-asthma-pest-allergies Source[/caption] If your asthma keeps flaring up no matter how much you clean, hidden pest allergens might be to blame. Even after extermination, tiny particles from cockroaches, dust mites, or rodents can linger in the air and trigger symptoms. Understanding the link between asthma and pest allergens, and taking the right pest control steps, can make a big difference in your home’s air quality and your breathing.

Pest Allergens, Asthma, and Dust Mite Allergy

Pest allergens are microscopic proteins found in the droppings, saliva, shed skin, or body parts of pests like cockroaches, mice, and dust mites. They’re "hidden triggers" because you might not see the insects or rodents themselves, but their allergenic particles can linger for months in carpets, HVAC filters, and soft furnishings. People with dust mite allergy are especially sensitive, since these allergens thrive in humidity and soft surfaces. What makes them so sneaky is that these lightweight, airborne allergens get stirred up every time you vacuum, walk on carpet, or turn on the air conditioning, continuously irritating the lungs and airways of anyone with asthma or allergies, especially kids. They’re not just "dust with legs." These biological fragments behave differently than environmental dust: they cling to humidity, spread easily through HVAC systems, and stay active for months. Pest allergens also build up behind walls, under appliances, and inside vents, where standard cleaning can’t reach. Even after a pest infestation has been treated by an exterminator, the allergens can remain long after the pests are gone. That’s why families often notice asthma symptoms well after extermination, it’s not reinfestation; it’s residue caused by lingering pest allergy triggers.
Allergies, Author Interviews, Pediatrics / 11.09.2025

MedicalResearch.com Interview with: [caption id="attachment_70637" align="alignleft" width="133"]Thomas B. Casale, M.D.Professor of Medicine and Pediatrics Chief of Clinical and Translational Research Division of Allergy and Immunology USF Health Morsani College of Medicine University of South Florida Tampa, Florida Dr. Casale[/caption] Thomas B. Casale, M.D. Professor of Medicine and Pediatrics Chief of Clinical and Translational Research Division of Allergy and Immunology USF Health Morsani College of Medicine University of South Florida Tampa, Florida MedicalResearch.com: What is the background for this study? Response: The data leading to FDA approval of neffy came from extensive pharmacokinetic and pharmacodynamic studies. As with previous epinephrine delivery devices, the FDA asked for data showing that after delivery of neffy the epinephrine blood levels and expected changes in pulse and blood pressure were similar to those achieved with injectable formulations of epinephrine. neffy performed as expected with blood levels of epinephrine bracketed by those achieved with EpiPen and a needle and syringe along with increases in pulse and blood pressure compatible with the epinephrine levels measured. Additionally, clinicians are interested in whether neffy would perform similarly in real clinical situations. The data from the neffy experience program provides real-world assurance that neffy can effectively treat acute allergic reactions. Given the large number of patients and the similar findings to those achieved with injectable epinephrine in previous studies, the data should provide assurance that neffy can be an effective substitute for injectable epinephrine in patients that desire a needle-free option. neffy
Allergies, Emergency Care / 07.04.2025

[caption id="attachment_67799" align="aligncenter" width="500"]medical-alert-badges Photo by Mikhail Nilov[/caption]  
Most people are living with health problems, and some individuals are currently struggling with at least one underlying health condition that affects their quality of life. According to the World Health Organization, the most prevalent health issues include noncommunicable diseases such as cancer, cardiovascular disease, and diabetes, which is responsible for 74 percent of all mortalities worldwide. More individuals are also coping with allergies, and about 20 percent of allergy patients have to deal with a debilitating form of their condition.
If you have an allergy or a serious health problem, you’re likely aware that proper medication and treatment is essential for your overall wellbeing. But to protect yourself, you also need to be prepared for medical emergencies, and one way to do so is by wearing a medical ID bracelet at all times. To ordinary citizens, a medical ID may look like just another typical fashion accessory. But for first responders and medical personnel, it can be the key to save your life. Here's how medical IDs can help you stay safe and manage allergies and medical conditions.
Allergies, Author Interviews, NEJM, Pediatrics / 11.02.2025

Editor's note:  Do not attempt immunotherapy for peanut or other allergens without the express direction of your health care provider. Life-threatening reactions may occur. MedicalResearch.com Interview with: [caption id="attachment_66501" align="alignleft" width="130"]Scott H. Sicherer, MDElliot and Roslyn Jaffe Professor of Pediatrics, Allergy and Immunology Director, Jaffe Food Allergy Institute Division Chief, Pediatric Allergy Medical Director, Clinical Research Unit Icahn School of Medicine at Mount Sinai Jack and Lucy Clark Department of Pediatrics Mount Sinai Kravis Children’s Hospital New York, NY 10029 Dr. Sicherer[/caption] Scott H. Sicherer, MD Elliot and Roslyn Jaffe Professor of Pediatrics, Allergy and Immunology Director, Jaffe Food Allergy Institute Division Chief, Pediatric Allergy Medical Director, Clinical Research Unit Icahn School of Medicine at Mount Sinai Jack and Lucy Clark Department of Pediatrics Mount Sinai Kravis Children’s Hospital New York, NY 10029 MedicalResearch.com: What is the background for this study? Response: About 2% of people have a peanut allergy.  While many of them are exquisitely allergic to tiny amounts, about half can tolerate a half a peanut kernel or more before they have symptoms, although the symptoms can be severe. Current studies and FDA approved treatments for peanut allergy have typically focused on people reacting to about half a peanut or less.  We thought that those with higher threshold may be more easily treated. We focused on children ages 4-14 years who we identified through a medically supervised feeding test as having allergic reactions from 443 to 5043 mg of peanut protein.  A peanut kernel is about 250 mg of peanut protein. The 73 children were randomized to a treatment (oral immunotherapy, OIT) using home-measured, store bought peanut butter versus continuing the standard of care, avoidance.  OIT involves medically supervised dosing going from a small amount to gradually increasing larger amounts.  The increases are done under direct allergist supervision, then the tolerated dose is taken at home daily. Families are given instructions about avoiding things that can cause a reaction from dosing, such as exercise after a dose, and to skip dosing for illness.  Dosing can cause reactions and they were instructed on how to recognize and treat any such reactions.   We did increases every 2 months. Most of the children (62) stayed in the study to be tested after the period of treatment, that aimed for having a level tablespoon of peanut butter each day. All of the treated children who completed testing (32) were able to eat 9 grams of peanut.  Only 3 of 30 who continued to avoid peanut were able to do this.
Allergies / 17.12.2024

Please consult your health care provider regarding your allergies and in particular any swollen lymph nodes. Swollen lymph nodes may be a sign of a serious illness, including malignancies and therefore should be addressed by your provider. Do not treat swollen lymph nodes with supplements or other products unless approved by your health care provider. Swollen lymph nodes can be uncomfortable and sometimes worrisome. They’re usually tied to infections, but did you know allergies can also trigger it? Although rare, allergies can sometimes cause lymph nodes to swell, making it important to understand this connection. The question is: What’s the relationship between allergies and swollen lymph nodes? allergies-swollen-nodes

Role of Lymph Nodes in the Immune System

Lymph nodes, small bean-shaped glands, sit throughout your body, with noticeable clusters in your neck, armpits, and groin. They trap harmful invaders like bacteria, viruses, and allergens, helping to keep you healthy and acting as the body’s safety net. These connect through lymphatic vessels, working to filter lymph fluid, and this very fluid carries white blood cells, proteins, and other components that strengthen your immunity. What happens when lymph nodes swell? It’s often a sign that the body is combating an infection or responding to another immune challenge. While infections are the most frequent cause of swelling, allergic reactions can also play a role by triggering the immune system.
Allergies, Author Interviews, Duke / 25.06.2024

MedicalResearch.com Interview with: [caption id="attachment_62084" align="alignleft" width="200"]Professor Soman Abraham PhDGrace Kerby Distinguished Professor of Pathology Duke University. Dr. Abraham led the research when working in the Emerging Infectious Diseases Research Programme at Duke-NUS Medical School in Singapore Prof. Abraham[/caption] Professor Soman Abraham PhD Grace Kerby Distinguished Professor of Pathology Duke University. Dr. Abraham led the research when working in the Emerging Infectious Diseases Research Programme at Duke-NUS Medical School in Singapore MedicalResearch.com: What is the background for this study? Response: The degranulation of mast cells (MCs) is a process that leads to allergic symptoms, ranging from itching, redness, and swelling of the tissue to severe and potentially life-threatening anaphylaxis involving multiple organ systems. According to the World Health Organization (WHO), more than 10 per cent of the global population suffers from food allergies. As allergy rates continue to rise, so does the incidence of food-triggered anaphylaxis and asthma worldwide. In view of the fact that allergic diseases are difficult to prevent or treat, we sought to understand the underlying basis for anaphylactic reactions.
Allergies, Exercise - Fitness / 06.06.2024

Understanding the Impact of Allergies on WorkoutsImagine gearing up for a workout, only to be hit with a sudden wave of sneezing or a stuffy nose. It's frustrating and can easily derail your fitness plans. Allergies can make even the most dedicated fitness enthusiasts want to give up. This scenario is all too common, especially during allergy season when pollen counts are high, and allergens are everywhere. The impact of allergies on workouts can be discouraging, but it doesn’t have to stop you from achieving your fitness goals. If this sounds like your experience, you’re not alone. Many people find their exercise routines interrupted by allergies. This article offers practical tips to help you stay motivated and manage your allergies during workouts. 1. Understanding the Impact of Allergies on Workouts Allergies can have a big impact on your physical performance. Symptoms like sneezing, congestion, itchy eyes, and fatigue can make it challenging to stick to your exercise routine. These symptoms can lower your stamina, make breathing harder, and reduce your overall workout intensity. Managing allergies effectively is key to maintaining a consistent fitness regimen and achieving your health goals.
Allergies / 16.05.2024

Allergy drops, not to be confused with allergy eye drops, have been gaining popularity for their convenient and effective approach to tackling pesky allergies. But are allergy drops the same as allergy immunotherapy? This option falls under the umbrella of allergy immunotherapy, and while allergy drops are allergy immunotherapy, not all allergy immunotherapy are allergy drops.  In this blog, we’ll explore allergy immunotherapy and allergy drops to help you better understand the best course of action for combatting your pesky allergies. 

Understanding Allergy Immunotherapy

Allergy immunotherapy (AIT) is a treatment that desensitizes the body to an allergen. It’s much unlike traditional allergy treatments, such as corticosteroids, decongestants, and antihistamines, because it focuses on the allergy, not the symptoms.  To understand how it works, we need to understand what an allergy is. Simply put, an allergy is a reaction in the body to a foreign substance called an allergen, such as bee venom or pet dander. When your body comes into contact with the allergen, your antibodies send a signal to specific cells that release chemicals, resulting in an allergic reaction.  allergies-allergy-pexelsThe reaction triggers the symptoms you recognize as your allergy, such as a runny nose and itchy eyes.  To desensitize your body to the allergen and help your body become less reactive, allergy immunotherapy delivers a small dose of the allergen under your skin or tongue. This small, incrementally increasing dose helps your body adjust, “training” it to become less sensitive.  It achieves this result by minimizing the production of “blocking” antibodies responsible for the reaction. Over time and with consistent doses, you may find that you can be exposed to the allergen with little to no reaction.  However, it’s important to note that everybody is different. Most people notice some results within the first year, but the most noticeable results usually take two to three years after beginning treatment. 
Allergies, Author Interviews, Dermatology, University of Michigan / 16.11.2023

MedicalResearch.com Interview with: [caption id="attachment_61065" align="alignleft" width="150"]Charles Schuler, MDAssistant Professor Allergy and Clinical Immunology & Mary H. Weiser Food Allergy Center University of Michigan Dr. Schuler[/caption] Charles Schuler, MD Assistant Professor Allergy and Clinical Immunology & Mary H. Weiser Food Allergy Center University of Michigan MedicalResearch.com: What is the background for this study? Response: Anaphylaxis is a severe allergic reaction that may include a skin rash, nausea, vomiting, difficulty breathing, and shock. Food anaphylaxis sends 200,000 people to the emergency room annually in the United States. Oral food challenges are when a patient ingests increasing doses up to a full serving of the suspected food allergen under supervision of a medical provider, usually an allergist. These oral food challenges are the diagnostic standard for food allergy/anaphylaxis as skin and blood allergy tests have high false positive rates. Although a highly accurate test, patients often experience anaphylaxis during oral food challenges necessitating an epinephrine injection.
Allergies, Author Interviews, CDC, Environmental Risks / 04.08.2023

MedicalResearch.com Interview with: Ann Carpenter DVM, MPH Epidemic Intelligence Service Officer Centers for Disease Control and Prevention Primary author of the recent CDC MMWR report.  [caption id="attachment_60720" align="alignleft" width="150"]Lone Star Tick Nymph, Alpha Gal Allergy, Meat allergy Lone Star Tick Nymph-CDC image[/caption] MedicalResearch.com: What is the background for this study? Would you briefly describe Alpha-gal Syndrome?  Response: Alpha-gal syndrome is an emerging and potentially life-threatening allergic condition that is associated with a tick bite. It is also called alpha-gal allergy, red meat allergy, or tick bite meat allergy. Increasing case studies and anecdotal reports suggested that AGS was a growing concern, but, prior to these studies, information on clinician awareness and the number of people impacted was not available at a national level.
Allergies, Author Interviews, Pediatrics / 10.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60414" align="alignleft" width="162"]Matthew Greenhawt Dr. Greenhawt[/caption] Matthew Greenhawt, MD, MBA, MSc Professor of Pediatrics Section of Allergy and Immunology Director, Food Challenge and Research Unit Children’s Hospital Colorado University of Colorado School of Medicine Anschutz Medical Campus Aurora, CO 80045   MedicalResearch.com: What is the background for this study? Is the incidence of peanut allergy in toddlers stabilizing with the earlier introduction of peanuts? Response: There exists an urgent unmet medical need for infants and toddlers living with peanut allergy. Peanut allergy affects approximately 2% of U.S. children and has been a growing public health problem over the past 20 years. In fact, the number of kids affected by peanut allergy has tripled in that time span. Peanut allergy is not likely to be naturally outgrown, and reactions can be severe. However, there is hope. There is growing evidence that the allergic immune system is more modifiable early in life. The EPITOPE study evaluated Viaskin Peanut in children ages 1 – 3 years of age. Viaskin Peanut is an investigational epicutaneous immunotherapy (EPIT) product, which uses the skin as a route to desensitize a patient to be less reactive to peanut. This is a daily therapy, worn between the shoulders on the back, which allows for non-oral peanut desensitization, which many parents find highly appealing.
Allergies, Author Interviews, Cancer Research, Dermatology, Melanoma / 17.03.2023

MedicalResearch.com Interview with: Jenni Komulainen University of Eastern Finland | UEF MedicalResearch.com: What is the background for this study? Response: The background for this study comes from the earlier findings that the skin cancer risk and atopic status have some connection, but the results have been inconsistent. The connection between atopy and skin cancers may be related to the stimulation of protective immune response or the predisposition to carcinogenesis through chronic inflammation. The aim of this study was to investigate if atopic disorders associate with skin cancers.
Allergies, Author Interviews, Dermatology / 09.03.2023

MedicalResearch.com Interview with: [caption id="attachment_60156" align="alignleft" width="150"]Nicholas Gulati, MD, PhDDirector, Early Detection of Skin Cancer and Oncodermatology Clinic The Kimberly and Eric J. Waldman Department of Dermatology Mount Sinai Health System New York, New York Dr. Gulati[/caption] Nicholas Gulati, MD, PhD Director, Early Detection of Skin Cancer and Oncodermatology Clinic The Kimberly and Eric J. Waldman Department of Dermatology Mount Sinai Health System New York, New York MedicalResearch.com: What is the background for this study? What is dupilumab primarily used for? Response: Dupilumab is a monoclonal antibody that inhibits a specific part of the immune system known as Th2 cells, which are important in the development of various diseases including atopic dermatitis (eczema) and asthma. Therefore, dupilumab has become one of the major treatments for these conditions. Given the increasing use of this drug, it is important to understand the safety of it in terms of cancer development, as that is currently largely unknown.
Allergies, Author Interviews, BMJ, Immunotherapy, Pediatrics / 13.01.2023

MedicalResearch.com Interview with: A/Prof Luke GrzeskowiakPhD | BPharm(Hons) | GCertClinEpid | AdvPracPharm | FSHP Associate Professor (Practitioner Fellow) Channel 7 Children’s Research Foundation Fellow in Medicines Use and Safety College of Medicine & Public Health Flinders University Affiliate Research Fellow – South Australian Health & Medical Research Institute (SAHMRI) Specialist Pharmacist – Flinders Women & Children, Flinders Medical Centre Adjunct Research Fellow – Faculty of Pharmacy and Pharmaceutical Sciences, Monash University Adjunct Research Fellow – Robinson Research Institute, The University of Adelaide  MedicalResearch.com: What is the background for this study? Response: Peanut allergy affects 1-3% of children in Western countries, making it the most common food-related allergen. Only a small percentage (20%) of children grow out of their peanut allergy, with allergen avoidance and provision of rescue medications for the management of allergic reactions being the recognised mainstay of treatment for many years. However, avoidance of peanuts provides many challenges for children and their caregivers and requires children and caregivers to be hypervigilant regarding peanut ingestion, creating a significant burden. This burden can have a real impact on quality of life for children and their families. In more recent years there has been emerging interest in what is referred to as oral immunotherapy as an active preventive treatment to reduce the risk of accidental peanut exposure. Oral immunotherapy involves exposing children to an extremely small dose of peanut, typically in the form of peanut flour, and then gradually increasing that dose over time to build tolerance. We have been looking at opportunities for making oral immunotherapy safer, which would then make it more suitable for more people. Our previous research showed that boiling peanuts alters its protein structure and allergic properties, meaning they were less likely to cause a severe allergic reaction, but were still able to improve tolerance to peanut allergens.
Allergies, Author Interviews, JAMA, Pediatrics / 06.07.2022

MedicalResearch.com Interview with: [caption id="attachment_59303" align="alignleft" width="150"]Victoria Soriano PhD Research Assistant/Officer, Population Allergy University of Melbourne Dr. Soriano[/caption] Victoria Soriano PhD Research Assistant/Officer, Population Allergy University of Melbourne   MedicalResearch.com:  What is the background for this study?  Response: Peanut allergy is one of the most common childhood food allergies, and children rarely grow out of it. The only proven way to prevent peanut allergy is to give infants age-appropriate peanut products in the first year of life. We previously showed there was a dramatic increase in peanut introduction from 2007-11 to 2018-19, following changes to infant feeding guidelines. We wanted to know if earlier peanut introduction would reduce peanut allergy in the general population (in Melbourne, Australia).
Allergies, Annals Internal Medicine, Author Interviews, Pharmacology / 29.03.2022

MedicalResearch.com Interview with: [caption id="attachment_58967" align="alignleft" width="150"]Chintan V. Dave, PharmD, PhD Assistant Professor Ernest Mario School of Pharmacy Institute for Health, Health Care Policy and Aging Institute Rutgers University Dr. Dave[/caption] Chintan V. Dave, PharmD, PhD Assistant Professor Ernest Mario School of Pharmacy Institute for Health, Health Care Policy and Aging Institute Rutgers University MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: The risks of anaphylaxis among intravenous (IV) iron products currently in use has not been assessed. Older adults have a higher risk of experiencing drug-induced anaphylaxis. Accordingly, our study objective was to elucidate the risk of anaphylaxis  among older adults receiving the five frequently used IV iron products: ferric carboxymaltose, ferumoxytol, ferric gluconate, iron dextran, and iron sucrose.
Allergies, Author Interviews / 26.02.2022

MedicalResearch.com Interview with: [caption id="attachment_58820" align="alignleft" width="200"]Edmond S. Chan Dr. Chan[/caption] Edmond S. Chan MD, FRCPC, FCSACI, FAAAAI Head | Division of Allergy & Immunology | Department of Pediatrics, Faculty of Medicine Clinical Professor, The University of British Columbia Clinical Investigator, BC Children's Hospital Research Institute BC Children's Hospital, Allergy Clinic Vancouver, BC  Canada Treasurer, CSACI (Canadian Society of Allergy & Clinical Immunology) MedicalResearch.com:  What prompted you to look at the safety of peanut oral immunotherapy specifically in this patient population? Response: Our previous research has investigated the overall safety of peanut oral immunotherapy (OIT) in preschool populations. However, we have not investigated the relationship between specific patient characteristics and the safety of OIT. Previous literature has shown that patient factors, such as age, gender, baseline sIgE levels, and atopic comorbidities have been shown to impact the safety of OIT for other food allergies and in older patients. However, no data exist on which factors predict safety of peanut OIT in preschool populations.
Allergies, Author Interviews, COVID -19 Coronavirus, Dermatology, UCSF / 27.11.2021

MedicalResearch.com Interview with: [caption id="attachment_58411" align="alignleft" width="225"]Carina M. Woodruff, MD Department of Dermatolog University of California, San Francisco Dr. Woodruff[/caption] Carina M. Woodruff, MD Department of Dermatolog University of California, San Francisco MedicalResearch.com: What is the background for this study? What are the main findings? Response: Rigorous hand hygiene has been an important component of the CDC's COVID-19 guidelines. With millions of Americans now using hand sanitizers regularly, we are seeing many more cases of hand dermatitis. Our study evaluated the key product features and most common allergens in the top-reviewed, commercial hand sanitizers sold by major US retailers. We found that the most common potential allergens were tocopherol, fragrance, propylene glycol and phenoxyethanol. Our study also showed that nearly 1 in 5 marketing claims on these products was misleading. For example, 70% of sanitizers with the marketing claim "hypoallergenic" included at least one common allergen in its formulation.
Allergies, Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies, Vanderbilt / 27.07.2021

MedicalResearch.com Interview with: [caption id="attachment_57827" align="alignleft" width="150"]Kimberly G. Blumenthal, MD, MSc Massachusetts General Hospital The Mongan Institute Boston, MA 02114 Dr. Blumenthal[/caption] Kimberly G. Blumenthal, MD, MSc Massachusetts General Hospital The Mongan Institute Boston, MA 02114 [caption id="attachment_57828" align="alignleft" width="100"]Matthew S. Krantz, MD Division of Allergy, Pulmonary and Critical Care Medicine Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee Dr. Krantz[/caption] Matthew S. Krantz, MD Division of Allergy, Pulmonary and Critical Care Medicine Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee   MedicalResearch.com: What is the background for this study? Response: During the initial COVID-19 vaccine campaign with healthcare workers in December 2020, there was an unexpected higher than anticipated rate of immediate allergic reactions after Pfizer and Moderna mRNA vaccines.  This prompted both patient and provider concerns, particularly in those with underlying allergic histories, on the associated risks for immediate allergic reactions with the mRNA vaccines. Because of the significantly improved effectiveness of two doses of an mRNA vaccine compared to one dose, it was important to determine if those who experienced immediate allergic reaction symptoms after their first dose could go on to tolerate a second dose safely.   
Allergies, Author Interviews / 24.02.2021

MedicalResearch.com Interview with:  Authors: Mike Kulis, Johanna Smeekens, Edwin Kim, Vladimir Zarnitsyn, Samirkumar Patel MedicalResearch.com: What is the background for this study? Response: Peanut allergy is an IgE-mediated disease affecting approximately 2% of young children in the United States. Over the past decade, various forms of immunotherapy have been investigated with the goal of repeated daily allergen exposure leading to a desensitized state. One of these therapies, oral immunotherapy, or OIT, received FDA approval for treating peanut allergy in January 2020 with Aimmune’s Palforzia drug. While OIT effectively induces desensitization in a majority of patients, there is a substantial burden related to side effects, with an ever-present risk of systemic anaphylaxis.
Allergies, Author Interviews, Immunotherapy / 11.02.2021

MedicalResearch.com Interview with: [caption id="attachment_56629" align="alignleft" width="200"]Dr. Cathy Leonard PhD Department of Infection and Immunity Luxembourg Institute of Health Luxembourg Dr. Leonard[/caption] Dr. Cathy Leonard PhD Department of Infection and Immunity Luxembourg Institute of Health Luxembourg MedicalResearch.com: What is the background for this study? Response: Cat allergy is a rapidly increasing phenomenon characterized by hypersensitivity and an excessive immune response to certain allergens associated with cats, among which the major allergen Fel d 1, a protein typically found in their saliva, on their skin and fur. Cat allergy manifestations can range from mild forms like itchy nose or sneezing to the development of severe symptoms such as rhinitis and asthma, with potentially fatal outcomes. Only Allergen‐specific immunotherapy (AIT )can ensure an effective and longer lasting treatment in the more advanced cases. AIT typically consists in the subcutaneous injection of gradually increasing doses of the allergen of interest, until a critical quantity is reached that induces long-term immune tolerance. Nevertheless, there is still the need to improve cat AIT in terms of efficacy and safety. We hypothesized that immune tolerance to the allergen could be boosted by improving the adjuvanticity of AIT solutions, thereby optimizing the production of antibodies against Fel d 1, while minimizing inflammation. 
Allergies, Author Interviews, Dermatology / 14.01.2021

MedicalResearch.com Interview with: Karan Lal, DO, Marketing Committee Member for the Society for Pediatric Dermatology, Dermatologist at UMass Memorial Medical Center. Dr. Lal discusses the recent study of a procedure to remove black dye from henna tattoos. MedicalResearch.com: What is the background for this study? Response: Para‐phenylenediamine, a dye frequently added to henna tattoos to create the black color, is a potent contact allergen. Severe contact dermatitis may arise within days even after the first application. Our objective was to develop a method for rapid and complete removal of para‐phenylenediamine‐containing black henna tattoos from the skin, an important problem many physicians are confronted with, but for which no simple method exists. 
Allergies, Author Interviews, OBGYNE, Pediatrics / 22.12.2020

MedicalResearch.com Interview with: Mia Stråvik PhD-student | Doktorand Department of Biology and Biological Engineering Division of Food and Nutrition Science Chalmers University of Technology MedicalResearch.com: What is the background for this study? Response: There is a need of research investigating the role of maternal diet during pregnancy and lactation on the baby’s allergy risk. Allergy is one of the most common chronic diseases of childhood, causing great suffering for the allergic child but also the entire family. Yet, the possibilities to cure and prevent this, in many cases life long, suffering are very limited. Previous research have indicated that maternal diet during pregnancy and lactation may affect the propensity of the child to develop an allergy, and diet is a factor you as a parent really can influence.
Allergies, Author Interviews, Dermatology / 06.12.2020

MedicalResearch.com Interview with: [caption id="attachment_24142" align="alignleft" width="128"]Dr. Jonathan L. Silverberg MD PhD MPH Assistant Professor in Dermatology Medical Social Sciences and Preventive Medicine Northwestern University, Chicago, Illinois Dr. Jonathan Silverberg[/caption] Jonathan Silverberg, MD, PHD, MPH Associate Professor Director of Clinical Research Director of Patch Testing George Washington University School of Medicine and Health Sciences Washington, DC MedicalResearch.com: What is the background for this study Response: Chronic hand eczema was previously shown to be associated with higher rates of allergic contact dermatitis. Yet, little is known about recent trends in North America with respect to the clinical presentation and allergen profile in chronic hand eczema. This study sought to determine the clinical characteristics and etiologies of hand eczema in a large North American cohort of adults referred for patch testing. The patients in the study were patch tested using the North American Contact Dermatitis Group’s allergen screening series.
Allergies, Author Interviews, Immunotherapy, Pediatrics / 04.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56134" align="alignleft" width="200"]Lianne Soller, PhD Allergy Research Manager, BC Children’s Hospital Allergy Clinic Vancouver, BC, Canada Dr. Soller[/caption] Lianne Soller, PhD Allergy Research Manager BC Children’s Hospital Allergy Clinic Vancouver, BC, Canada MedicalResearch.com: What is the background for this study? Response: Peanut oral immunotherapy (also known as OIT) has been studied for many years in clinical trials and has been found to be safe and effective in preschoolers. However, we know that clinical trials do not always reflect what happens in the real world. We wanted to see study whether peanut OIT would work as well in the real world. This is a follow up of our preschool peanut OIT safety study published in April 2019 which noted only 0.4% severe reactions and 4% epinephrine use during build-up.
Allergies, Author Interviews, Dermatology / 17.11.2020

MedicalResearch.com Interview with: Yashu Dhamija MD Dr. Thomas Schmidlin, MD Cleveland Clinic Akron General  MedicalResearch.com: What is the background for this study? Response: We are seeing an increased use of face masks in the COVID-19 pandemic and while that is encouraged and necessary to limit the spread of disease in the general publication, it can mean challenges for some individuals. Patients with known sensitizations to allergens contained in face masks may experience rash or irritation with commonly used face coverings. It is also possible for patients without a history of contact dermatitis to become sensitized to allergens after wearing facial coverings more regularly, thus leading to new cases of contact dermatitis (CD) in individuals with no known prior history of contact dermatitis.
Allergies, Author Interviews, ENT / 07.10.2020

MedicalResearch.com Interview with: [caption id="attachment_55567" align="alignleft" width="133"]Brent A. Senior, MD, FACS, FARS Professor of Otolaryngology/Neurosurgery Vice Chairman for Clinical Affairs Nathaniel and Sheila Harris Distinguished Professor Chief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery Department of Otolaryngology-Head and Neck Surgery University of North Carolina at Chapel Hill Chapel Hill, NC Dr. Senior[/caption] Brent A. Senior, MD, FACS, FARS Professor of Otolaryngology/Neurosurgery Vice Chairman for Clinical Affairs Nathaniel and Sheila Harris Distinguished Professor Chief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery Department of Otolaryngology-Head and Neck Surgery University of North Carolina at Chapel Hill Chapel Hill, NC MedicalResearch.com: What is the background for this study? How common is the problem of chronic rhinosinusitis with nasal polyps? Response: Chronic rhinosinusitis (CRS) is a very common illness in the United States and around the world, estimated to impact 2-14% of the US population. Chronic rhinosinusitis with polyps is a particularly challenging form of the disease marked by significant impact on quality of life, and being challenging to treat with significant recurrences of symptoms despite standard medical and surgical treatment. Inhaled intranasal steroids are standard therapy for patients with CRS including those with nasal polyps. However, many patients continue to have significant nasal symptoms despite treatment with these medications. This study was designed to answer the question of whether patients who had been receiving treatment with inhaled intranasal steroids and failed were improved by using EDS-FLU. Results were obtained by pooling data from two previous studies of the use of EDS-FLU in patients with CRS, called Navigate 1 and 2.